Full Press Release Details
Announces Annual General Meeting of Shareholders
Germany, May 22, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and
developing highly targeted cancer immunotherapies, announced today that the Annual General Meeting of Shareholders will be held
on Tuesday, June 20, 2017. The meeting will be held at Hilton Amsterdam, Apollolaan 138, 1077 BG Amsterdam, The Netherlands. The
meeting will start at 2:30 p.m. CET.
and agenda of the general meeting are available free of charge in the Investor Relations section under "Notice to convene
the Annual General Meeting of Shareholders of Affimed N.V." of Affimed's corporate website at www.affimed.com. They are
also available on the SEC's website at www.sec.gov.
AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK-
and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more
information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: IR@affimed.com
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: a.alexandru@affimed.com